{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T18:04:49Z","timestamp":1785175489290,"version":"3.55.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Das Wells-Syndrom z\u00e4hlt zur heterogenen Gruppe der eosinophilen Dermatosen und wird h\u00e4ufig mit systemischen Glukokortikosteroiden behandelt. Wir berichten \u00fcber den erfolgreichen Einsatz des Interleukin-5-Antik\u00f6rpers Mepolizumab bei einer 76-j\u00e4hrigen Patientin mit Wells-Syndrom. Der Fall verdeutlicht, dass Mepolizumab nach Versagen von Standardtherapien eine wirksame Therapieoption darstellen kann. Ein Einsatz ist auch ohne das Vorliegen einer Bluteosinophilie oder weitere eosinophile Erkrankungen in Betracht zu ziehen.<\/jats:p>","DOI":"10.1007\/s00105-026-05758-3","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:38:56Z","timestamp":1785173936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rasches Ansprechen eines Wells-Syndroms ohne Bluteosinophilie oder weitere eosinophile Erkrankungen auf Mepolizumab","Rapid response to mepolizumab in Wells syndrome despite absence of blood eosinophilia or other eosinophilic disorders"],"prefix":"10.1007","author":[{"given":"Finn","family":"Abeck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Hansen-Abeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ohm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Siemann-Harms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Booken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. W.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"1","key":"5758_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-025-04305-9","volume":"317","author":"A Ahmed","year":"2025","unstructured":"Ahmed\u00a0A, Cahn\u00a0B, Haber\u00a0R (2025) Wells syndrome: emerging triggers and treatments- an updated systematic review. Arch Dermatol Res 317(1):805. https:\/\/doi.org\/10.1007\/s00403-025-04305-9","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"5758_CR2","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/ddg.15964","volume":"24","author":"G Ciccarese","year":"2026","unstructured":"Ciccarese\u00a0G, Rosato\u00a0WA, Drago\u00a0F, Meduri\u00a0AR, Ambrogio\u00a0F, De Marco\u00a0A et\u00a0al (2026) Bullous Wells\u2019 syndrome successfully treated with omalizumab. J\u00a0Dtsch Dermatol Ges 24(5):657\u2013659. https:\/\/doi.org\/10.1111\/ddg.15964","journal-title":"J Dtsch Dermatol Ges"},{"issue":"10","key":"5758_CR3","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/ddg.13943","volume":"17","author":"M Peckruhn","year":"2019","unstructured":"Peckruhn\u00a0M, Elsner\u00a0P, Tittelbach\u00a0J (2019) Eosinophilic dermatoses. J\u00a0Dtsch Dermatol Ges 17(10):1039\u20131051. https:\/\/doi.org\/10.1111\/ddg.13943","journal-title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft"},{"issue":"6","key":"5758_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jdcr.2018.02.011","volume":"4","author":"S Herout","year":"2018","unstructured":"Herout\u00a0S, Bauer\u00a0WM, Schuster\u00a0C, Stingl\u00a0G (2018) Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab. JAAD Case Rep 4(6):548\u2013550. https:\/\/doi.org\/10.1016\/j.jdcr.2018.02.011","journal-title":"JAAD Case Rep"},{"issue":"7","key":"5758_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/ddg.14151","volume":"18","author":"D Terhorst-Molawi","year":"2020","unstructured":"Terhorst-Molawi\u00a0D, Altrichter\u00a0S, R\u00f6wert\u00a0J, Magerl\u00a0M, Zuberbier\u00a0T, Maurer\u00a0M et\u00a0al (2020) Effective treatment with mepolizumab in a patient with refractory Wells syndrome. J\u00a0Dtsch Dermatol Ges 18(7):737\u2013739. https:\/\/doi.org\/10.1111\/ddg.14151","journal-title":"J Dtsch Dermatol Ges"},{"issue":"11","key":"5758_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15799","volume":"35","author":"OC Trica","year":"2022","unstructured":"Trica\u00a0OC, Mocan\u00a0LP, Boit-Trapcea\u00a0R (2022) Mepolizumab is highly effective in a rare case of Wells syndrome: Eosinophilic granulomatosis with polyangiitis overlap. Dermatol Ther 35(11):e15799. https:\/\/doi.org\/10.1111\/dth.15799","journal-title":"Dermatol Ther"},{"key":"5758_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jdcr.2024.08.014","volume":"53","author":"NB Curkovic","year":"2024","unstructured":"Curkovic\u00a0NB, Yuan\u00a0IH, Bahrani\u00a0E, Keefe\u00a0MS, Kahwash\u00a0BM (2024) Mepolizumab-responsive recurrent eosinophilic eruption without peripheral eosinophilia. JAAD Case Rep 53:43\u201346. https:\/\/doi.org\/10.1016\/j.jdcr.2024.08.014","journal-title":"JAAD Case Rep"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05758-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05758-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05758-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:38:57Z","timestamp":1785173937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05758-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":7,"alternative-id":["5758"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05758-3","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.\u00a0Abeck, I.\u00a0Hansen-Abeck, F.\u00a0Ohm, U.\u00a0Siemann-Harms, N.\u00a0Booken und S.W.\u00a0Schneider geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}